Blyth Christopher C, Chen Sharon C A, Slavin Monica A, Serena Carol, Nguyen Quoc, Marriott Deborah, Ellis David, Meyer Wieland, Sorrell Tania C
Centre for Infectious Diseases and Microbiology, Westmead Hospital, Hawkesbury Road, Westmend, New South Wales 2145, Australia.
Pediatrics. 2009 May;123(5):1360-8. doi: 10.1542/peds.2008-2055.
The purpose of this work was to identify differences in incidence, risk factors, microbiology, treatment, and clinical outcome of candidemia in neonates, children, and adults that might impact on management.
Cases of candidemia in Australia were identified prospectively by blood culture surveillance over 3 years. Episodes of candidemia in neonatal, pediatric, and adult age groups were analyzed and compared.
Of 1005 incident cases, 33 occurred in neonates, 110 in children, and 862 in adults. The respective annual age-specific incidences were 4.4, 0.9, and 1.8 per 100,000 population. Prematurity and ICU admission were major risk factors in neonates. Hematologic malignancy and neutropenia were significantly more frequent in children than in neonates and adults. Diabetes, renal disease, hemodialysis, and recent surgery were more common in adults. Candidemia was attributed to a vascular access device in 58% of neonates, 70% of children, and 44% of adults. Candida albicans caused approximately 48% of cases in all of the age groups. Candida parapsilosis was significantly more common in neonates and children (42% and 38% vs 15%). Candida glabrata was infrequent in neonates and children (9% and 3% vs 17%). Significantly more isolates from children were susceptible to fluconazole compared with those from adults (95% vs 75%). Fluconazole-resistant candidal isolates were infrequent in all of the age groups. Neonates and children were more likely to receive amphotericin B compared with adults. Adults were more likely to receive fluconazole. Survival rates at 30 days were 78% in neonates, 90% in children, and 70% in adults.
This study identifies significant differences in candidemia in neonates, children, and adults. Neonatologists and pediatricians must consider age-specific differences when interpreting adult studies and developing treatment and prevention guidelines.
本研究旨在确定新生儿、儿童和成人念珠菌血症在发病率、危险因素、微生物学、治疗方法及临床结局方面的差异,这些差异可能会影响治疗管理。
通过对澳大利亚3年的血培养监测前瞻性地确定念珠菌血症病例。对新生儿、儿童和成人年龄组的念珠菌血症发作情况进行分析和比较。
在1005例确诊病例中,33例发生在新生儿,110例发生在儿童,862例发生在成人。各年龄组的年发病率分别为每10万人4.4例、0.9例和1.8例。早产和入住重症监护病房是新生儿的主要危险因素。血液系统恶性肿瘤和中性粒细胞减少症在儿童中比在新生儿和成人中更为常见。糖尿病、肾病、血液透析和近期手术在成人中更为常见。58%的新生儿、70%的儿童和44%的成人念珠菌血症与血管通路装置有关。白色念珠菌在所有年龄组中导致约48%的病例。近平滑念珠菌在新生儿和儿童中明显更为常见(分别为42%和38%,而成人为15%)。光滑念珠菌在新生儿和儿童中较少见(分别为9%和3%,而成人为17%)。与成人分离株相比,儿童分离株对氟康唑的敏感性明显更高(95%对75%)。耐氟康唑的念珠菌分离株在所有年龄组中都很少见。与成人相比,新生儿和儿童更有可能接受两性霉素B治疗。成人更有可能接受氟康唑治疗。新生儿、儿童和成人的30天生存率分别为78%、90%和70%。
本研究确定了新生儿、儿童和成人念珠菌血症的显著差异。新生儿科医生和儿科医生在解读成人研究以及制定治疗和预防指南时必须考虑年龄特异性差异。